<DOC>
	<DOCNO>NCT00663845</DOCNO>
	<brief_summary>This study conduct US obtain information efficacy , safety , duration erection flexible-dose regime vardenafil compare placebo ( dummy medication pharmacological activity ) , patient co-morbid factor associate erectile dysfunction ( also call impotence ) . The duration erection endpoint assess patient utilized stopwatch timing attempt sexual intercourse . Elevated level total cholesterol low level HDL may result atherosclerosis induce erectile dysfunction . Vardenafil ( Levitra ) approve Food Drug Administration treatment erectile dysfunction . While intent ass effect vardenafil blood lipid , study provide prospective data men diagnose ED dyslipidemia .</brief_summary>
	<brief_title>Assessing Efficacy Safety Flexible Dosing With Vardenafil Subjects With Erectile Dysfunction Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Males ED 6 month , accord NIH Consensus Statement ( inability attain and/or maintain penile erection sufficient satisfactory sexual performance ) Stable heterosexual relationship 6 month Between 18 &lt; 65 year age Diagnosed dyslipidemia treat stable dose statin ( generic equivalent ) &gt; /=3 month Screening . In addition , subject must remain stable dose statin ( generic equivalent ) throughout study additional therapy treat dyslipidemia initiate InternationaI Index Erectile Function Erectile Function domain score &lt; 25 , denote mild severe ED Visit 2 Primary hypoactive sexual desire History myocardial infarction , stroke lifethreatening arrhythmia within prior 6 month Nitrate therapy Other exclusion criterion apply accord US Product Information</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Male Erectile Dysfunction</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Vardenafil</keyword>
</DOC>